{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:28:35Z","timestamp":1794623315383,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"DOI":"10.1186\/s13054-026-06106-6","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:35:53Z","timestamp":1780040153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Triple M overlap syndrome in the intensive care unit: differential diagnosis and management"],"prefix":"10.1186","volume":"30","author":[{"given":"Chail","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh Shetty","family":"Rajalbandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Seshadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluseyi","family":"Abidoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Battley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"6106_CR1","doi-asserted-by":"publisher","unstructured":"Stanley R, Flanagan S, Reilly DO, Kearney E, Naidoo J, Dowling CM. Immunotherapy through the lens of non-small cell lung cancer. Cancers (Basel). 2023;15(11). Epub 20230530. https:\/\/doi.org\/10.3390\/cancers15112996. PubMed PMID: 37296957; PubMed Central PMCID: PMC10252117.","DOI":"10.3390\/cancers15112996"},{"key":"6106_CR2","doi-asserted-by":"publisher","first-page":"1582887","DOI":"10.3389\/fimmu.2025.1582887","volume":"16","author":"B Wang","year":"2025","unstructured":"Wang B, Xiang Y, Liu X, Pan X, Peng L, Ma J. Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions. Front Immunol. 2025;16:1582887. https:\/\/doi.org\/10.3389\/fimmu.2025.1582887. Epub 20250703.","journal-title":"Front Immunol"},{"issue":"1","key":"6106_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025;392(1):11\u201322. Epub 20240915. doi: 10.1056\/NEJMoa2407417. PubMed PMID: 39282897; PubMed Central PMCID: PMC12080919.","journal-title":"N Engl J Med"},{"issue":"3","key":"6106_CR4","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11523-025-01143-7","volume":"20","author":"ZA Yochum","year":"2025","unstructured":"Yochum ZA, Braun DA. Immunotherapy for renal cell carcinoma-what more is to come? Target Oncol. 2025;20(3):467\u201383. https:\/\/doi.org\/10.1007\/s11523-025-01143-7. Epub 20250410.","journal-title":"Target Oncol"},{"issue":"36","key":"6106_CR5","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073\u2013126. https:\/\/doi.org\/10.1200\/JCO.21.01440. Epub 20211101.","journal-title":"J Clin Oncol"},{"issue":"12","key":"6106_CR6","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s40265-025-02243-4","volume":"85","author":"PE Abraham","year":"2025","unstructured":"Abraham PE, Johnson DB. Long-term toxicities of immune checkpoint inhibitors. Drugs. 2025;85(12):1535\u201349. https:\/\/doi.org\/10.1007\/s40265-025-02243-4. Epub 20250930.","journal-title":"Drugs"},{"key":"6106_CR7","doi-asserted-by":"publisher","unstructured":"Montemayor K, Ghanbar MI, Koch AL, Suresh K, Stephens RS. Managing immune checkpoint inhibitor pneumonitis in the ICU. CHEST Crit Care. 2025;3(1). https:\/\/doi.org\/10.1016\/j.chstcc.2024.100126.","DOI":"10.1016\/j.chstcc.2024.100126"},{"key":"6106_CR8","doi-asserted-by":"publisher","unstructured":"Pichon S, Zebian G, Bureau C, Levy C, Lacombe C, Desmedt E et al. Life-threatening immune-related adverse events in the intensive care unit: a narrative review. Intensive Care Med. 2025;51(12):2289\u2013304. Epub 20251022. https:\/\/doi.org\/10.1007\/s00134-025-08155-x. PubMed PMID: 41123622.","DOI":"10.1007\/s00134-025-08155-x"},{"key":"6106_CR9","unstructured":"National Comprehensive Cancer Network (NCCN). Management of immune checkpoint inhibitor-related toxicities. Version 1.2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1548. Accessed 16 May 2026."},{"issue":"13","key":"6106_CR10","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1016\/j.jacc.2019.07.079","volume":"74","author":"S Ball","year":"2019","unstructured":"Ball S, Ghosh RK, Wongsaengsak S, Bandyopadhyay D, Ghosh GC, Aronow WS, et al. Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week. J Am Coll Cardiol. 2019;74(13):1714\u201327. PubMed PMID: 31558256.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"6106_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/14740338.2020.1738382","volume":"19","author":"AM Haugh","year":"2020","unstructured":"Haugh AM, Probasco JC, Johnson DB. Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf. 2020;19(4):479\u201388. Epub 20200311. doi: 10.1080\/14740338.2020.1738382. PubMed PMID: 32126176; PubMed Central PMCID: PMC7192781.","journal-title":"Expert Opin Drug Saf"},{"key":"6106_CR12","doi-asserted-by":"publisher","first-page":"774170","DOI":"10.3389\/fphar.2022.774170","volume":"13","author":"V Albarran","year":"2022","unstructured":"Albarran V, Chamorro J, Rosero DI, Saavedra C, Soria A, Carrato A, et al. Neurologic toxicity of immune checkpoint inhibitors: a review of literature. Front Pharmacol. 2022;13:774170. https:\/\/doi.org\/10.3389\/fphar.2022.774170. Epub 20220214.","journal-title":"Front Pharmacol"},{"issue":"1","key":"6106_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1474-4422(23)00369-1","volume":"23","author":"A Farina","year":"2024","unstructured":"Farina A, Villagr\u00e1n-Garc\u00eda M, Vogrig A, Zekeridou A, Mu\u00f1iz-Castrillo S, Velasco R, et al. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. Lancet Neurol. 2024;23(1):81\u201394. https:\/\/doi.org\/10.1016\/S1474-4422(23)00369-1.","journal-title":"Lancet Neurol"},{"issue":"12","key":"6106_CR14","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217\u201338. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001.","journal-title":"Ann Oncol"},{"key":"6106_CR15","doi-asserted-by":"publisher","unstructured":"Lipe DN, Qdaisat A, Krishnamani PP, Nguyen TD, Chaftari P, El Messiri N, et al. Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review. Diagnostics (Basel). 2024;14(16). https:\/\/doi.org\/10.3390\/diagnostics14161794. Epub 20240816.","DOI":"10.3390\/diagnostics14161794"},{"key":"6106_CR16","doi-asserted-by":"publisher","first-page":"1597259","DOI":"10.3389\/fimmu.2025.1597259","volume":"16","author":"A Sanchez-Camacho","year":"2025","unstructured":"Sanchez-Camacho A, Torres-Zurita A, Gallego-Lopez L, Hernandez-Pacheco R, Silva-Romeiro S, Alamo de la Gala MDC, et al. Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review. Front Immunol. 2025;16:1597259. PubMed PMID: 40406130; PubMed Central PMCID: PMC12095175.","journal-title":"Front Immunol"},{"key":"6106_CR17","doi-asserted-by":"publisher","first-page":"101192","DOI":"10.1016\/j.lanepe.2024.101192","volume":"50","author":"L Plomp","year":"2025","unstructured":"Plomp L, Chassepot H, Psimaras D, Maisonobe T, Mensi E, Leonard-Louis S, et al. Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study. Lancet Reg Health Eur. 2025;50:101192. PubMed PMID: 39896961; PubMed Central PMCID: PMC11782875.","journal-title":"Lancet Reg Health Eur"},{"issue":"4","key":"6106_CR18","doi-asserted-by":"publisher","first-page":"A5381","DOI":"10.1016\/j.chest.2024.06.3201","volume":"166","author":"P Pham","year":"2024","unstructured":"Pham P, Heppler M, Jackson IP, Plambeck RW. Immune checkpoint inhibitor-related myasthenia gravis, myositis, hepatitis, and myocarditis. Chest. 2024;166(4):A5381\u20132. https:\/\/doi.org\/10.1016\/j.chest.2024.06.3201.","journal-title":"Chest"},{"issue":"3","key":"6106_CR19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/anae.16453","volume":"80","author":"S Carter","year":"2025","unstructured":"Carter S, Wigmore T. Immunotherapy on ICU: a narrative review. Anaesthesia. 2025;80(3):299\u2013310. Epub 20250108. doi: 10.1111\/anae.16453. PubMed PMID: 39776055.","journal-title":"Anaesthesia"},{"issue":"13","key":"6106_CR20","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.3390\/cancers17132063","volume":"17","author":"M Furlepa","year":"2025","unstructured":"Furlepa M, Watts I, Carr AS. Management of Triple M syndrome: a narrative review of immune checkpoint inhibitor-induced myasthenia gravis, myositis and myocarditis. Cancers (Basel). 2025;17(13):2063. https:\/\/doi.org\/10.3390\/cancers17132063. Epub 20250620.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"6106_CR21","doi-asserted-by":"publisher","first-page":"ytaf019","DOI":"10.1093\/ehjcr\/ytaf019","volume":"9","author":"E Wadden","year":"2025","unstructured":"Wadden E, Lai C, Grivas P, Bhatia S, Portuguese AJ, Salem JE, et al. Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report. Eur Heart J Case Rep. 2025;9(2):ytaf019. https:\/\/doi.org\/10.1093\/ehjcr\/ytaf019. Epub 20250217.","journal-title":"Eur Heart J Case Rep"},{"issue":"10","key":"6106_CR22","doi-asserted-by":"publisher","first-page":"e032620","DOI":"10.1161\/JAHA.123.032620","volume":"13","author":"A Sharma","year":"2024","unstructured":"Sharma A, Alexander G, Chu JH, Markopoulos A, Maloul G, Ayub MT, et al. Immune checkpoint inhibitors and cardiotoxicity: a comparative meta-analysis of observational studies and randomized controlled trials. J Am Heart Assoc. 2024;13(10):e032620. https:\/\/doi.org\/10.1161\/JAHA.123.032620.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"6106_CR23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","volume":"7","author":"H Safa","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019;7(1):319. https:\/\/doi.org\/10.1186\/s40425-019-0774-y. Epub 20191121.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"6106_CR24","doi-asserted-by":"publisher","first-page":"100772","DOI":"10.1016\/j.jtocrr.2024.100772","volume":"6","author":"A Alghabban","year":"2025","unstructured":"Alghabban A, Corke L, Katzberg H, Bril V, Barnett-Tapia C, Mason W, et al. Myasthenia gravis in patients treated with immune checkpoint inhibitors. JTO Clin Res Rep. 2025;6(5):100772. https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100772. Epub 20241122.","journal-title":"JTO Clin Res Rep"},{"key":"6106_CR25","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3389\/fneur.2020.00634","volume":"11","author":"YT Huang","year":"2020","unstructured":"Huang YT, Chen YP, Lin WC, Su WC, Sun YT. Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol. 2020;11:634. Epub 20200716. doi: 10.3389\/fneur.2020.00634. PubMed PMID: 32765397; PubMed Central PMCID: PMC7378376.","journal-title":"Front Neurol"},{"key":"6106_CR26","doi-asserted-by":"crossref","unstructured":"Naqash AR, Kouzy R, Pandey A, Shaikh M, Olubowale O, Barkauskas DA et al. Triple M overlap syndrome (TMOS): evaluating immune checkpoint inhibitor-related overlap syndrome of myocarditis, myositis and myasthenia gravis using an international pharmacovigilance database. J Clin Oncol. 2024;42(16_suppl):2643.","DOI":"10.1200\/JCO.2024.42.16_suppl.2643"},{"issue":"16suppl","key":"6106_CR27","first-page":"TPS3157","volume":"41","author":"JE Salem","year":"2023","unstructured":"Salem JE, Allenbach Y, Vozy A, Cautela J, Johnson DB, Moslehi JJ, et al. Abatacept for immune checkpoint inhibitor-associated myocarditis (ATRIUM): phase 3, investigator-initiated, randomized, placebo-controlled study to evaluate the efficacy and safety of abatacept compared to placebo in hospitalized patients with immune checkpoint inhibitor-associated myocarditis. J Clin Oncol. 2023;41(16suppl):TPS3157.","journal-title":"J Clin Oncol"},{"issue":"7","key":"6106_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","volume":"17","author":"JJ Wright","year":"2021","unstructured":"Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021;17(7):389\u201399. https:\/\/doi.org\/10.1038\/s41574-021-00484-3. Epub 20210419.","journal-title":"Nat Rev Endocrinol"},{"key":"6106_CR29","doi-asserted-by":"publisher","first-page":"102021","DOI":"10.1016\/j.toxrep.2025.102021","volume":"14","author":"Y Vaez-Gharamaleki","year":"2025","unstructured":"Vaez-Gharamaleki Y, Akbarzadeh MA, Jadidi-Niaragh F, Mahmoodpoor A, Sanaie S, Hosseini MS. Dermatologic toxicities related to cancer immunotherapy. Toxicol Rep. 2025;14:102021. https:\/\/doi.org\/10.1016\/j.toxrep.2025.102021. Epub 20250405.","journal-title":"Toxicol Rep"},{"issue":"1","key":"6106_CR30","doi-asserted-by":"publisher","first-page":"e2021155","DOI":"10.5826\/dpc.1101a155","volume":"11","author":"Z Apalla","year":"2021","unstructured":"Apalla Z, Papageorgiou C, Lallas A, Delli F, Fotiadou C, Kemanetzi C, et al. Cutaneous adverse events of immune checkpoint inhibitors: a literature review. Dermatol Pract Concept. 2021;11(1):e2021155. https:\/\/doi.org\/10.5826\/dpc.1101a155. Epub 20210129.","journal-title":"Dermatol Pract Concept"},{"key":"6106_CR31","unstructured":"Immune checkpoint inhibitor cardiotoxicity. do not miss the forest for the trees. ASCO Daily News. https:\/\/dailynews.ascopubs.org\/do\/immune-checkpoint-inhibitor-cardiotoxicity-do-not-miss-forest-trees. Accessed 16 May 2026."},{"issue":"3","key":"6106_CR32","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jaccao.2025.01.020","volume":"7","author":"YC Chen","year":"2025","unstructured":"Chen YC, Dolladille C, Rao A, Palaskas NL, Deswal A, Lehmann L, et al. Immune checkpoint inhibitor myocarditis and left ventricular systolic dysfunction. JACC CardioOncol. 2025;7(3):234\u201348. https:\/\/doi.org\/10.1016\/j.jaccao.2025.01.020 . PubMed PMID: 40246381; PubMed Central PMCID: PMC12046861.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"6106_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jaccao.2020.12.001","volume":"3","author":"F Thuny","year":"2021","unstructured":"Thuny F, Alexandre J, Salem JE, Mirabel M, Dolladille C, Cohen-Solal A, et al. Management of immune checkpoint inhibitor-induced myocarditis: the French Working Group\u2019s plea for a pragmatic approach. JACC CardioOncol. 2021;3(1):157\u201361. PubMed PMID: 34396318; PubMed Central PMCID: PMC8352226.","journal-title":"JACC CardioOncol"},{"key":"6106_CR34","doi-asserted-by":"publisher","first-page":"1372861","DOI":"10.3389\/fneur.2024.1372861","volume":"15","author":"Y Qin","year":"2024","unstructured":"Qin Y, Chen S, Gui Q, Zhang T, Li Y, Du Z, et al. Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review. Front Neurol. 2024;15:1372861. https:\/\/doi.org\/10.3389\/fneur.2024.1372861. Epub 20240403.","journal-title":"Front Neurol"},{"issue":"17supplement2","key":"6106_CR35","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1212\/WNL.0000000000203688","volume":"100","author":"S Habib","year":"2023","unstructured":"Habib S, Ahmed H, Al-Awwad A, Sung S. Immune checkpoint inhibitors related new onset myasthenia gravis: case series (P4-5.028). Neurology. 2023;100(17supplement2):4021. https:\/\/doi.org\/10.1212\/WNL.0000000000203688.","journal-title":"Neurology"},{"key":"6106_CR36","doi-asserted-by":"publisher","first-page":"101453","DOI":"10.1016\/j.gore.2024.101453","volume":"54","author":"L Montag","year":"2024","unstructured":"Montag L, Piver R, Vidalin A, Johnson M, Rungruang B, Higgins R. Pembrolizumab-induced myasthenia gravis: two patients\u2019 experiences. Gynecol Oncol Rep. 2024;54:101453. https:\/\/doi.org\/10.1016\/j.gore.2024.101453. Epub 20240704.","journal-title":"Gynecol Oncol Rep"},{"issue":"5","key":"6106_CR37","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaccao.2022.11.005","volume":"4","author":"J Moslehi","year":"2022","unstructured":"Moslehi J, Salem JE. Immune checkpoint inhibitor myocarditis treatment strategies and future directions. JACC CardioOncol. 2022;4(5):704\u20137. Epub 20221220. doi: 10.1016\/j.jaccao.2022.11.005. PubMed PMID: 36636442; PubMed Central PMCID: PMC9830216.","journal-title":"JACC CardioOncol"},{"issue":"5","key":"6106_CR38","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","volume":"75","author":"M Awadalla","year":"2020","unstructured":"Awadalla M, Mahmood SS, Groarke JD, Hassan MZO, Nohria A, Rokicki A, et al. Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis. J Am Coll Cardiol. 2020;75(5):467\u201378. PubMed PMID: 32029128; PubMed Central PMCID: PMC7067226.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"6106_CR39","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/ejhf.2265","volume":"23","author":"NL Palaskas","year":"2021","unstructured":"Palaskas NL, Segura A, Lelenwa L, Siddiqui BA, Subudhi SK, Lopez-Mattei J, et al. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. Eur J Heart Fail. 2021;23(10):1725\u201335. https:\/\/doi.org\/10.1002\/ejhf.2265. Epub 20210625.","journal-title":"Eur J Heart Fail"},{"key":"6106_CR40","doi-asserted-by":"publisher","unstructured":"Power JR, Dolladille C, Ozbay B, Procureur A, Ederhy S, Palaskas NL et al. Immune checkpoint inhibitor-associated myocarditis: a novel risk score. Eur Heart J. 2025. Epub 20250618. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf315. PubMed PMID: 40569849.","DOI":"10.1093\/eurheartj\/ehaf315"},{"issue":"5","key":"6106_CR41","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","volume":"13","author":"JE Salem","year":"2023","unstructured":"Salem JE, Bretagne M, Abbar B, Leonard-Louis S, Ederhy S, Redheuil A, et al. Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov. 2023;13(5):1100\u201315. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1180 . PubMed PMID: 36815259.","journal-title":"Cancer Discov"},{"key":"6106_CR42","doi-asserted-by":"publisher","unstructured":"Marco C, Simo M, Alemany M, Casasnovas C, Dominguez R, Vilarino N et al. Myasthenia gravis induced by immune checkpoint inhibitors: an emerging neurotoxicity in neuro-oncology practice: case series. J Clin Med. 2022;12(1). Epub 20221224. https:\/\/doi.org\/10.3390\/jcm12010130. PubMed PMID: 36614930; PubMed Central PMCID: PMC9821391.","DOI":"10.3390\/jcm12010130"},{"issue":"7Supplement1","key":"6106_CR43","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1212\/01.wnl.0001051900.06940.ea","volume":"103","author":"S Hewitt","year":"2024","unstructured":"Hewitt S, Wang D, Poursheykhi M, Patel S, Shah S. Immune checkpoint inhibitor related myositis\/myasthenia gravis overlap syndrome treated with eculizumab. Neurology. 2024;103(7Supplement1):S131\u20132. https:\/\/doi.org\/10.1212\/01.wnl.0001051900.06940.ea.","journal-title":"Neurology"},{"issue":"6","key":"6106_CR44","doi-asserted-by":"publisher","first-page":"e200314","DOI":"10.1212\/NXI.0000000000200314","volume":"11","author":"S Rossi","year":"2024","unstructured":"Rossi S, Farina A, Malvaso A, Dinoto A, Fionda L, Cornacchini S, et al. Clinical course of neurologic adverse events associated with immune checkpoint inhibitors: focus on chronic toxicities. Neurol Neuroimmunol Neuroinflamm. 2024;11(6):e200314. 0000000000200314. PubMed PMID: 39298719; PubMed Central PMCID: PMC11413993.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"35","key":"6106_CR45","doi-asserted-by":"publisher","first-page":"105543","DOI":"10.1016\/j.jaccas.2025.105543","volume":"30","author":"T Vockenhuber","year":"2025","unstructured":"Vockenhuber T, Baldinger L, Clausen J, Kollias G, Schmid M, Schneiderbauer-Porod S, et al. Successful use of ruxolitinib for steroid-refractory immune checkpoint inhibitor-associated myocarditis. JACC Case Rep. 2025;30(35):105543. https:\/\/doi.org\/10.1016\/j.jaccas.2025.105543.","journal-title":"JACC Case Rep"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-026-06106-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-026-06106-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-026-06106-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:14:22Z","timestamp":1785518062000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13054-026-06106-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6106"],"URL":"https:\/\/doi.org\/10.1186\/s13054-026-06106-6","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of the clinical details included in this manuscript was obtained from both patients.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"395"}}